


History of Pleuromutilin




(+)-Pleuromutilin

GROUP MEETING


3/20/2018

KIMBERLY HILBY



Antibiotics: 1940-1970




R = Bn, penicillin
R = 2,6-methoxyphenyl, Methicillin



Tetracycline



erthromycin




gentamicin

Isolation of Pleuromutilin

- Isolated from the Pleurotus Mutilus, an edible mushroom, in 1951



Clitopilus Scyphoides



Initial Bioactivity


Bioactivity was shown to be moderate but effective against gram positive bacteria

Strain	Dilutions per ml
Bacillus mycoides	125
Bacillus subtilis	8
Escherichia coli	500
Klebsiella pneumoniae	1
Mycobacterium smegma	32
Pseudomonas aeruginosa	>1000
Staphylococcus aureus	0.25




Clitopilus Scyphoides


Initial Attempts of Characterization




Characterization




Kuhn-Roth Oxidation







PMR Spectrum




IR for Compound showed a band 1735 cm^{-1} which is characteristic of a cyclopentanone




Structure of Pleuromutilin





Matched by looking at Mass Spec
Fragmentation




Hydrofluorene core was ruled
out because IR showed evidence
of Cyclopentanone ring



indane with some other ring can
rearrange and cyclize to give
the Fluorene




(+)-pleuromutilin




(+)-mutilin, R=H

(+)-pleuromutilin, R=COCH₂OH


Hypothesized Biosynthesis




Evidence of terpene cyclization




Biosynthesis of Pleuromutilin



Evidence of Hydride/Methyl Shift




Evidence of 1,5-hydride transfer




Gibbons's Synthesis


Dr. Grant Gibbons's synthesis was done at Harvard University in the labs of the late Professor R.B. Woodward





Gibbons's Synthesis of Tricycle




Gibbons's Synthesis to Core



Gibbons's Elaboration of Ring




Boeckman Retrosynthetic Analysis




Professor Robert
Boeckman from the
University of
Rochester


Boeckman Racemic Synthesis




Boeckman Racemic Synthesis



Boeckman Racemic Synthesis



Initial work on Mode of Action



Inhibits protein synthesis





Fig.5. Effect of compound Ib on EF-T-catalyzed binding of Phe-tRNA to ribosomes in the presence of poly(U). All other details are listed in Materials and Methods





Fig.1. Scatchard plot of the equilibrium dialysis data from binding of compound Ib to ribosomes. The ribosome concentration of 202 A_{260} units/ml was kept constant for all measurements


Does this by not allowing Phe-tRNA to bind to site A

First SAR studies



-OR	-R ₁	-R ₂	Staph. aureus	<i>Mycoplasma hominis</i>	<i>Mycoplasma Gallisepticum</i>	<i>Mycoplasma hyorhinis</i>
H	COCH ₂ OH	vinyl	.5	.3	.3	2
H	COCH ₂ S(CH ₂) ₂ NEt ₂	vinyl	0.05	0.01	0.006	0.3
H	COCH ₂ NEt ₂	vinyl	1.4	5	5	3
H	COCH ₂ S(CH ₂) ₂ NEt ₂	ethyl	0.1	0.02	0.02	0.6
H	COCH ₂ SC ₆ H ₄ COOH	vinyl	1	>100	0.2	100
H	COCH ₂ OAc	vinyl	0.5	0.5	8	0.5
Ac	COCH ₂ OAc	vinyl	>10	>10	10	-

New Drugs from these SAR Studies




- Tiamulin(1979) and Valnemulin(1999) are both used in veterinary medicine to treat pulmonary and intestinal infections in pigs




Why not more human drugs developed?

Rapidly and extensively
metabolized by cytochrome
P450 metabolism in vivo

GSK drug approved in 2007-only
Pleuromutilin type drug approved for
human use- topical antibiotic for skin
infections




Recent Work on Method of Action




Group Problem


Propose a mechanism and model for the reaction



Group Problem




Epi-pleuromutilin SAR




Gram negative bacteria:

- Channels to pump out harmful toxins to the bacteria
- Resistance is higher because of covering around the cell wall

In 2015 a patent was filed for a pleuromutilin derivative that was effective against gram negative bacteria




Procter Retrosynthetic Analysis




Professor David Procter at the University of Manchester reported the first non racemic synthesis of Pleuromutilin

Procter Core Synthesis




(+)-trans-dihydrocarvone


Procter Key Step




Procter Further Elaboration of Core




Procter End Game




Herzon Retrosynthetic Analysis



Professor Seth Herzon
from Yale University




Herzon Synthesis Part 1




Zn(CH₃)₂,

3


Problems with Addition






1,4-Addition into the Enone





Solution to the Problem




Alkyne and Aldehyde Coupling




End Game



Final Step of Synthesis




Reisman Retrosynthetic Analysis



Professor Sarah
Reisman at Caltech
University

Z(pleuromutilin) : $R^1 = \text{Me}$, $R^2 = \text{CH}_2\text{CH}_2\text{OTrt}$
E(epi-pleuromutilin) : $R^1 = \text{CH}_2\text{CH}_2\text{OTrt}$, $R^2 = \text{Me}$

Reisman Total Synthesis



The troublesome step








Figure 2. Plausible mechanism of the enantioselection.

End Game



Conclusion



Author	Racemic/Non Racemic	Longest Linear Step	Overall Yield
Gibbons	Racemic	31	.7%
Boeckman	Racemic	27	.4%
Procter	Non Racemic	34	.7%
Herzon	Non Racemic	20	.7%
Reisman	Non Racemic	18	2.5%